5 completed, 2 withdrawn, 1 not yet recruiting, 1 recruiting. 9 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 9 | Completed 5, Withdrawn 2, Not yet recruiting 1, Recruiting 1 |
Follow Attention Deficit Hyperactivity Disorder (ADHD): new trials by email Literature Review of Attention Deficit Hyperactivity Disorder (ADHD) trials Research Report on Attention Deficit Hyperactivity Disorder (ADHD)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The TEAM Study - Treatment Efficacy for Autism/Attention Using Mixed Amphetamine Adderall XR (mixed salts amphetamine), Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Autism | Phase 4 | Recruiting | Gagan Joshi | 196 | 2026-02-01 | 2026-03-06 |
| PHArmaCokinetics of methYLphenidate in Adult Patients With Attention-Deficit /Hyperactivity Disorder PHArmacoKinetics of methYLphenidate in adult patients with ADHD: comparison between patients with and without OBesity. - Attention Deficit Hyperactivity Disorder (ADHD), Obesity (Body Mass Index &Amp;Amp;gt;30 kg/m2) | Phase 4 | Not yet recruiting | University Hospital, Tours | 30 | 2025-09-01 | 2025-08-13 |
| A 6-week Study to Evaluate the Safety and Efficacy of Quillichew ERCT in 4-5 Year Old Children With ADHD. methylphenidate HCl ERCT, Placebo - Attention Deficit Hyperactivity Disorder (ADHD), Attention Deficit Hyperactivity Disorder | Phase 4 | Withdrawn | Pfizer | 2018-10-31 | 2018-11-01 | |
| Safety, Tolerability and PK Study of Methylphenidate HCl ERCT in 4-5 Year Old Children With ADHD. methylphenidate HCl ERCT - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Withdrawn | Pfizer | 2018-09-25 | 2018-11-01 | |
| Crossover Study to Evaluate the Efficacy of AR11 in Pediatric Patients With ADHD in a Laboratory Classroom Setting AR11, Placebo - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Arbor Pharmaceuticals, Inc. | 97 | 2013-12-01 | 2020-07-21 |
| Lisdexamfetamine Dimesylate 2-year Safety Study in Children and Adolescents With Attention-Deficit/Hyperactivity Disorder (ADHD) Lisdexamfetamine dimesylate - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Shire | 314 | 2011-07-07 | 2021-06-10 |
| A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants Osmotic Release Oral System Methylphenidate Hydrochloride (OROS-MPH), No intervention - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Xian-Janssen Pharmaceutical Ltd. | 194 | 2009-12-01 | 2014-09-17 |
| Cardiovascular Study of Lisdexamfetamine in Healthy and Hypertensive Attention Deficit Hyperactivity Disorder Adults Lisdexamfetamine - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Massachusetts General Hospital | 24 | 2008-04-01 | 2012-09-24 |
| Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) in Children Aged 6-12 Diagnosed With ADHD Vyvanse (lisdexamfetamine dimesylate) - Attention Deficit Hyperactivity Disorder (ADHD) | Phase 4 | Completed | Shire | 318 | 2007-06-28 | 2022-03-10 |
Attention Deficit Disorder with Hyperactivity (9) · Autism Spectrum Disorder (1) · Autistic Disorder (1) · Obesity (1) · Overweight (1)
Attention Deficit and Disruptive Behavior Disorders (9) · Mental Disorders (9) · Neurodevelopmental Disorders (9) · Body Weight (1) · Child Development Disorders, Pervasive (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Pathological Conditions, Signs and Symptoms (1) · Signs and Symptoms (1)
Lisdexamfetamine Dimesylate (3) · Adiposity (1) · Amphetamine (1) · SLI381 (1)
Pfizer (2) · Shire (2) · Arbor Pharmaceuticals, Inc. (1) · Gagan Joshi (1) · Massachusetts General Hospital (1) · University Hospital, Tours (1) · Xian-Janssen Pharmaceutical Ltd. (1)
United States (4) · Belgium (1) · China (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Netherlands (1) · Poland (1) · Romania (1) · Spain (1) · Sweden (1) · United Kingdom (1)
Gagan Joshi, MD (1) · Laurence Downey, MD (1) · Paul Hammerness, MD (1)
PMID 20035583, PMID 21173426, PMID 21186969, PMID 26608976, PMID 28667569, PMID 29383572, PMID 29790103, PMID 30972657